Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYJ76M
|
|||
| Drug Name |
JNJ-75276617
|
|||
| Synonyms |
JNJ-6617
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
| Company |
JOHNSON & JOHNSON
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Menin-MLL1 interaction (MEN1-KMT2A PPI) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04811560) A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants With Acute Leukemia. U.S.National Institutes of Health. | |||
| REF 2 | Targeting the undruggable: menin inhibitors ante portas. J Cancer Res Clin Oncol. 2023 Sep;149(11):9451-9459. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.